Richard Mason is head of J&J Innovation for the EMEA region, and identifying and investing in the most promising early-stage drug ideas outside the company is one of his key roles.
This ‘open innovation’ strategy is being pursued by all the big pharma companies – and now it’s simply a matter of who executes best on this approach.